Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Detecting Ctdna Using Personalized Structural Variants To Forecast Recurrence In Localized Soft Tissue Sarcoma.
  1. Home
  3. Detecting Ctdna Using Personalized Structural Variants To Forecast Recurrence In Localized Soft Tissue Sarcoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Staged Resection with Temporizing VAC and Local Recurrence for Soft Tissue Sarcomas: A Multi-Institutional Review.

Cancers·2026
Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer.

Cancer research·2026
Same author

Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy.

Nature communications·2026
Same author

A Consensus Approach to the Incorporation of Total Neoadjuvant Therapy in a Treatment Algorithm for Stage I-III Resectable Rectal Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

NeoCircle: pre- and post-operative circulating tumor DNA dynamics predicts survival in neoadjuvant-treated early breast cancer.

EMBO molecular medicine·2026
Same journal

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft Tissue Sarcoma.

Changsu L Park1, Elizabeth G Demicco2, Karen Howarth3

  • 1Princess Margaret Cancer Centre Toronto, Ontario Canada.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 4, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Detecting circulating tumor DNA (ctDNA) using structural variants (SVs) shows high sensitivity in soft tissue sarcoma (STS). Postoperative ctDNA detection in localized STS indicates a high risk of early metastatic recurrence.

More Related Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Related Experiment Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genomics

Background:

  • Soft tissue sarcoma (STS) is a complex cancer with frequent structural variants (SVs).
  • Localized STS recurrence rates remain high despite surgery and radiation, with controversial adjuvant therapy roles.
  • Assessing circulating tumor DNA (ctDNA) for molecular residual disease detection is crucial.

Purpose of the Study:

  • To evaluate the feasibility and sensitivity of tracking tumor-informed SVs via ctDNA in localized STS.
  • To correlate ctDNA dynamics with clinical outcomes during perioperative and surveillance periods.
  • To inform future adjuvant systemic therapy trials for localized STS.

Main Methods:

  • Personalized assays targeting 4-16 SV-breakpoints were developed for ctDNA detection.
  • Blood samples were collected from localized, high-risk STS patients at diagnosis, post-radiation, and postoperatively (≤8 weeks).
  • ctDNA levels were monitored longitudinally and correlated with radiologic surveillance and clinical outcomes.

Main Results:

  • The SV-based ctDNA assay demonstrated 97% sensitivity at baseline in 32 STS patients.
  • Postoperative ctDNA detection (≤8 weeks) in 18% of patients predicted early metastatic recurrence within one year.
  • ctDNA negativity in the postoperative window was associated with delayed recurrence, preceded by detectable ctDNA.

Conclusions:

  • SV-based ctDNA detection is a sensitive and feasible method for localized STS.
  • Early postoperative ctDNA detection is a strong indicator of imminent metastatic recurrence.
  • These findings support the use of ctDNA in designing personalized adjuvant therapy trials for STS.